Pronidesivir(GS-441524) is a nucleoside analog antiviral that inhibits the replication of feline coronavirus and is widely used as a core treatment approach for FIP. NeoFipronis® provides GS-441524 in 30mg scored oral tablets for practical, accurate dosing and convenient long-term administration.

NeoFipronis® (Pronidesivir) is officially registered by the Ministry of Agriculture and Forestry (MAF) (Reg. No.: ຢສ-F020326-0156) and produced under the oversight of the Department of Livestock and Fisheries in a GMP-aligned manufacturing environment. Batches are subject to quality testing and traceability controls.

No. NeoFipronis® is an over-the-counter (OTC) veterinary medicine. It does not require a veterinary prescription for purchase in markets where it is registered as an OTC product.
However, because feline infectious peritonitis (FIP) is a serious disease, consultation with a veterinarian is strongly recommended before starting treatment. A veterinarian can help confirm the diagnosis, determine the appropriate dosage based on the cat’s weight and FIP presentation, and monitor the cat’s condition during the treatment course.
NeoFipronis® tablets are intended for veterinary use in cats only and should be used according to the product instructions or under veterinary guidance.

A commonly referenced course length is 84 days. Do not reduce the dose or stop treatment without veterinary guidance, as under-dosing may increase relapse risk. After treatment, an observation period with follow-up testing is often recommended.

Dosing is typically expressed in mg/kg/day and depends on clinical presentation. Final dosing should be determined by a licensed veterinarian. Common reference dosing:

• Wet FIP: 15 mg/kg/day
• Dry FIP: 15 mg/kg/day
• Ocular FIP: 30 mg/kg/day
• Neurological FIP: 30 mg/kg/day

NeoFipronis® tablets are 30mg scored tablets and can be split into 15mg halves for more precise dose adjustment.

Cats often gain weight during recovery. Because dosing is calculated as mg per kg of body weight, weekly weigh-ins help keep dosing aligned with the current weight and reduce the risk of under-dosing.

Many cats begin to show improvement within 2–7 days, such as better appetite, improved energy, reduced fever, and gradual weight gain. Response time can vary depending on severity and individual factors.

Under veterinary supervision, GS-441524 is generally well tolerated. Some cats may show mild digestive sensitivity or changes in liver enzymes. Regular monitoring and supportive care (as advised by a veterinarian) can help manage treatment smoothly.

The dosage of NeoFipronis® should be determined based on your cat’s body weight and the type of FIP. While the product instructions provide general dosing guidance, it is recommended to consult a veterinarian before making any dose adjustments.

Use the verification page to confirm batch/lot information and follow official guidance. If anything looks inconsistent, contact support for confirmation.

If you miss one dose, give it as soon as possible and resume the normal schedule. If multiple doses are missed, consult your veterinarian before continuing. Consistent dosing is critical for treatment success.

NeoFipronis® is an oral tablet. Oral administration can reduce stress and may be easier for long-term home care, compared with injections.

Purchase through official NeoFipronis® support channels to ensure authenticity, documentation, and reliable assistance with ordering and shipping.

Please have your cat’s current weight, the suspected or confirmed FIP type (wet, dry, ocular, or neurological), and recent blood test results (if available). This helps align quantity planning and monitoring discussions with your veterinarian.

Support may include dosing guidance, product verification assistance, collaboration support with licensed veterinarians, and order/shipping help.